Related Experiment Video
Updated: Jan 10, 2026

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy
Published on: September 9, 2020
Mavacamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy During Active Chemotherapy
Juan Caro-Codón1, Silvia Valbuena-López1, Ismael Ghanem Cañete2
1Cardiology Department, La Paz University Hospital, IdiPaz Research Institute, Madrid, Spain.
Mavacamten effectively treated obstructive hypertrophic cardiomyopathy (oHCM) in a patient undergoing chemotherapy for colon cancer. This cardiac myosin inhibitor improved symptoms and quality of life despite active malignancy.
Area of Science:
- Cardio-oncology
- Cardiovascular Medicine
- Pharmacology
Background:
- Obstructive hypertrophic cardiomyopathy (oHCM) treatment in patients with active malignancy is not well-established.
- Cardiac myosin inhibitors represent a novel therapeutic class for oHCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Mitral Stenosis III: Medical Management
Cardiomyopathy IV: Restrictive Cardiomyopathy
Myocarditis III: Medical Management

